Dihong Meisu (地红霉素)地红霉素
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 西安利君制药有限责任公司Chinese legal name: 西安利君制药有限责任公司
主要成分Active Ingredients
- 地红霉素Dihong Meisu
药物知识说明
地红霉素是一种在国家药监局注册认定的药品。该药品含有地红霉素-16fd1443等成分。
该药品关联的活性成分包括：地红霉素Dihong Meisu。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：西安利君制药有限责任公司Chinese legal name: 西安利君制药有限责任公司。
您可以探索含有相同成分的其他药品：地红霉素-16fd1443成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 地红霉素) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 地红霉素Dihong Meisu.
Manufacturers recorded for this product: 西安利君制药有限责任公司Chinese legal name: 西安利君制药有限责任公司.
Explore other medicines containing the same ingredient: 地红霉素 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 地红霉素Recorded Chinese name: 地红霉素
- 规格Specification: 0.125g0.125 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 西安利君制药有限责任公司Chinese legal name: 西安利君制药有限责任公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20051767
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20051767
Manufacturer
Chinese legal name: 西安利君制药有限责任公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20051767
生产企业
西安利君制药有限责任公司(国产)
适应症
适用于慢性支气管炎、社区获得性肺炎、咽炎、扁桃体炎等。用于支原体、衣原体引起的泌尿系统感染。本品不适用于败血症。
用法用量
1.每次500mg，每天1次，吃饭时服用，疗程根据病情为7～14天。老年人不需更改剂量。 2.对轻度肝功能不足和慢性肾衰竭的患者亦不必调整剂量。
不良反应
1.不良反应主要为消化系统反应，如腹痛、恶心、腹泻、呕吐、消化不良、便秘、稀便、口干、口腔溃疡、味觉改变等。
2.其他有头痛、头晕、咳嗽加剧、皮疹、瘙痒等。
3.实验室检查可见血小板增加；ALT、AST胆红素、肌酐上升等。
禁忌
对本品过敏者禁用。对大环内酯类抗生素过敏者。
注意事项
1.对于溶血性链球菌所致的腭扁桃体炎须至少给药10天以上，以减少复发率和风湿热综合征。
2.对轻度肝、胆、肾损伤者不需调整剂量。
贮藏
密封，置阴凉处。
规格
0.125g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.